In vitro treatment of the HG-SOC cell line PMOV10, a dual receptor antagonist targeting both ETAR and ETBR, macitentan, a drug approved for treating pulmonary arterial hypertension, was shown to inhibit the gene expression of VEGF, ET-1 and CTGF through the YAP/HIF-1α/mutp53/β-arr1 network by preventing the accumulation of HIF-1α and YAP in the nucleus [17,20]. The gene discussed is HIF1A; the disease is pulmonary arterial hypertension.